RARE PHOTOS: 2 - The Real Truth

Miracle new Alzheimer's drug which slows cognitive decline of disease to be rolled out

The Food and Drug Administration (FDA) has approved the much awaited drug Leqembi which has been shown to slow the cognitive decline caused by Alzheimer’s, the most common type of dementia

Daily Mirror · Jul 7, 2023

US government approves Alzheimer’s drug to slow cognitive decline

Some insurances, including the government-run Medicare, refused to pay for the drug until it received full approval.

Al Jazeera · Jul 6, 2023

Eisai Alzheimer's drug gets full US approval, widening access to the therapy

Eisai Co.’s Alzheimer’s drug Leqembi gained full approval from U.S. regulators Thursday, a move expected to widen access to the first drug cleared based on its ability to slow progression of the mind-robbing disease.

Tribune News Service · Jul 6, 2023

An Alzheimer's drug is on the way, but getting it may still be tough. Here's why

The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.

WEKU · Jun 26, 2023

Experimental Alzheimer's drug endorsed for full approval by FDA advisers

Leqembi could become the first treatment of its kind to receive traditional approval from the FDA.

Axios · Jun 9, 2023

Alzheimer's drug gets FDA panel's backing, setting the stage for broader use

U.S. health advisers are backing the full approval of an Alzheimer's drug that received preliminary approval last year

The Independent UK · Jun 9, 2023

UK on verge of new dawn for dementia treatments, says taskforce chair

Today’s generation of older people could be last to face untreatable Alzheimer’s – but only if NHS overhauls care

The Guardian - UK · Apr 26, 2023

The VA will pay for some to get new Alzheimer’s drug

The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.

Tribune News Service · Mar 13, 2023

Why a new Alzheimer's drug is having a slow US debut

The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away

The Independent UK · Feb 4, 2023

3 Biotech Stocks to Get in on Before It’s Too Late

Rapidly growing market for personalized medicines and revolutionary technologies like 3D bioprinting is expected to bolster the biotech industry. Moreover, rising government initiatives should support its growth. Hence, quality biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal buys. Continue reading.

StockNews.com · Feb 1, 2023